Modulite: a simple solution to a difficult problem.
The development of HFA-based pMDIs has proved difficult due to differences in the physico-chemical properties of CFC and HFA propellants. However, the development of solution formulations instead of suspensions has provided a way to formulate products whose cloud characteristics can be modulated in a controlled manner by permitting different formulation and device hardware variables. The new approach has proved successful in formulating several different drugs including steroids and has now been applied to developing a formoterol Modulite solution formulation characterized by good chemical stability, delivery performance, and clinical results.
Lewis
D A
DA
Vectura Ltd., Chippenham, UK. david.lewis@vectura.com
Ganderton
D
D
Meakin
B J
BJ
Brambilla
G
G
D000335:Aerosol Propellants / Q000592:standards; D001993:Bronchodilator Agents / Q000008:administration & dosage; D002626:Chemistry, Pharmaceutical; D004355:Drug Stability; D004983:Ethanolamines / Q000008:administration & dosage; D000068759:Formoterol Fumarate; D006801:Humans; D036501:Metered Dose Inhalers; D013678:Technology, Pharmaceutical
D000335:Aerosol Propellants; D001993:Bronchodilator Agents; D004983:Ethanolamines; D000068759:Formoterol Fumarate